Investor Relations

Latest Financial Results

Q1 2024

Quarter Ended Mar 31, 2024

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Company Overview

SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.

Stock Snapshot

IR Contacts


1 Evertrust Plaza
13th Floor
Jersey City, NJ 07302
T: (201) 884-5485

Investor Relations

LifeSci Advisors
Irina Koffler
T: 646-970-4681


Ivor Macleod
Chief Financial Officer

Transfer Agent

American Stock Transfer & Trust Company, LLC
10150 Mallard Creek Road
Suite 307
Charlotte, NC 28262
T: 800-937-5449

Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.